Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease - Data from the multicenter CEDATA-GPGE registry study

• Hauptverfasser: Merle Claßen (Verfasst von), Jan de Laffolie (Verfasst von), Martin Claßen (Verfasst von), Alexander Schnell (Verfasst von), Keywan Sohrabi (Verfasst von), André Hoerning (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background and aimsIn recent years, biological agents, such as anti-TNF-α blockers, have been introduced and have shown efficacy in pediatric patients with inflammatory bowel disease (IBD). Here, the prescription mode differentiated into a first/second line application, and efficacy and side effects...